Serum NGAL in Critically Ill Children in ICU from a Single Center in Egypt

Table 4

Comparative study of patients group according to NGAL, Urea, and creatinine at admission (day zero) and 3rd day and their classification according to severity to 3 subgroups: NAKI, AKI − D, and AKI + D.

Parameter	NAKI	AKI − D	AKI + D	Test of significance	𝑃
	𝑁=47	𝑁=8	𝑁=5
NGAL-0 (ng/mL)
Median	84	100.5	120	1.37^b	0.24
Range	(34–210)	(74–115)	(66–148)
NGAL-3 (ng/mL)
Median	105	184	350	3.08^b	0.04*
Range	(34–530)	(42–395)	(150–550)
Urea-0 (mg/dL)
Median	34.5	38	65	5.91^b	0.01*
Range	(15–116)	(28–57)	(42.5–788)
Urea-3 (mg/dL)
Median	38	84.1	113.4	0.08^b	0.76
Range	(18–310)	(40–228)	(7–178)
Creatinine-0 (mg/dL)
X ± SD	0.6 ± 0.23	0.8 ± 0.27	0.94 ± 0.15	𝐹=6.22	0.004*
Creatinine-3 (mg/dL)
X ± SD	0.73 ± 0.36	2.25 ± 1.01	3.7 ± 1.1	𝐹=77.9	0.000*

^bMann-Whitney test; 𝐹: Fisher test; *significant.